Imbruvica pulled in $4.1 billion in U.S. sales (2018)
Imbruvica treats only B cell cancers with much smaller patient populations then ours can treat.
So a $21 billion BO of Cytodyn would seem to be quite the underbid.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-